On-Demand Webinar

From Dosimetry to Dose Decisions: How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Learn how dosimetry, clinical pharmacology, pharmacometrics, QSP, and regulatory strategy support dose optimization for therapeutic…

Hunter Stephens, PhD2026 年 7 月 17 日

Publication

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

Explore how model-based meta-analysis supports dose optimization, trial design, and regulatory decisions, plus emerging roles…

Certara2026 年 7 月 16 日

Publication

Population pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer’s dementia

Explore how population pharmacokinetic and exposure–response modeling informed brexpiprazole dosing in Japanese patients with agitation…

Certara2026 年 7 月 16 日

Blog

When to conduct hepatic impairment studies and when modeling may be enough

How to decide if a hepatic impairment study is required, choose the right study design,…

Zoe Barter2026 年 7 月 13 日

Blog

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…

Hunter Stephens, PhD2026 年 7 月 7 日

Publication

Population PK Modeling Supporting the Aripiprazole Two-Injection Start Regimen in Japanese Patients

Learn how population PK modeling and simulation supported a regulatory strategy for a simplified aripiprazole…

Danielle Pillsbury2026 年 7 月 7 日

Guide

5 Key Principles of Modern PK/PD in 2026

Explore other Phoenix solutions to enhance your PK/PD workflow and discover how Phoenix helps you…

Certara2026 年 6 月 30 日

Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

Alekhya Lavu, PhD, PharmD2026 年 6 月 26 日

Announcement

Certara 推出“Bio Venture Catalyst”计划，助力新兴生物科技企业降低投资风险并加速研发进程

Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…

Danielle Pillsbury2026 年 6 月 23 日

Blog Case Study

63 次迭代仍未收敛：When RsNLME succeeded where other PK/PD solutions couldn’t

After 63 failed runs on a 16-ODE neutropenia model, RsNLME achieved PK/PD convergence on the…

Stephen Duffull2026 年 6 月 23 日

临床药理学

From Dosimetry to Dose Decisions: How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis

Population pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer’s dementia

When to conduct hepatic impairment studies and when modeling may be enough

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Population PK Modeling Supporting the Aripiprazole Two-Injection Start Regimen in Japanese Patients

5 Key Principles of Modern PK/PD in 2026

Enhancing clinical trials with real-world evidence in pregnancy research

Certara 推出“Bio Venture Catalyst”计划，助力新兴生物科技企业降低投资风险并加速研发进程

63 次迭代仍未收敛：When RsNLME succeeded where other PK/PD solutions couldn’t

订阅时事通讯

快捷链接

解决方案

联系我们